Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet

• 資料種別: 博士論文
• タイトル: Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet
• 著者・編者: Bavuu, Oyunbileg; Fukuda, Daiju; Ganbaatar, Byambasuren; Matsuura, Tomomi; Ise, Takayuki; Kusunose, Kenya; Yamaguchi, Koji; Yagi, Shusuke; Yamada, Hirotsugu; Soeki, Takeshi; Wakatsuki, Tetsuzo; Sata, Masataka
• 著者標目: Bavuu, Oyunbileg; Fukuda, Daiju; Ganbaatar, Byambasuren; Matsuura, Tomomi; Ise, Takayuki; Kusunose, Kenya; Yamaguchi, Koji; Yagi, Shusuke; Yamada, Hirotsugu; Soeki, Takeshi; Wakatsuki, Tetsuzo; Sata, Masataka
• 出版事項: Elsevier
• 出版年月日等: 2022-08-09
• 出版年（W3CDTF）: 2022-08-09
• 並列タイトル等: 選択的ミネラルコルチコイド受容体遮断薬であるエサキセレノンは、高脂肪食投与マウスにおけるインスリン感受性を改善する
• タイトル（掲載誌）: European Journal of Pharmacology
• 巻号年月日等（掲載誌）: 931
• 掲載巻: 931
• 掲載ページ: 175190-
• ISSN（掲載誌）: ISSN : 0014-2999; ISSN : 1879-0712
• 授与機関名: 徳島大学
• 授与年月日: 2023-09-30
• 報告番号: 甲第3756号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Esaxerenone; Mineralocorticoid receptor; Aldosterone; Insulin resistance; Insulin signaling
• 対象利用者: 一般
• 一般注記: Background: Esaxerenone is a novel, non-steroidal selective mineralocorticoid receptor (MR) blocker. MR activation plays a crucial role in the development of cardiovascular and metabolic diseases. In this study, we investigated the effects of esaxerenone on various metabolic parameters in mice. Materials and methods: Esaxerenone (3 mg/kg/day) was orally administered to high-fat diet (HFD)-fed male C57BL/6 mice. Mice fed a normal diet (ND) served as controls. Glucose and insulin tolerance, plasma lipid levels, and transaminase levels were assessed as metabolic parameters. Macrophage accumulation in the adipose tissue was evaluated using histological analysis. 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes were used for in vitro experiments. Gene expression and insulin signaling were examined using quantitative RT-PCR and western blotting, respectively. Results: HFD successfully induced insulin resistance compared with that in ND. Esaxerenone ameliorated insulin resistance (P < 0.05) without altering other metabolic parameters, such as the lipid profile. Esaxerenone administration tended to decrease plasma transaminase levels compared with those in the non-treated group. In the adipose tissue, esaxerenone decreased macrophage accumulation (P < 0.05) and increased the expression levels of adiponectin and PPARγ. Aldosterone significantly decreased the expression levels of PPARγ and adiponectin in 3T3-L1 adipocytes. Furthermore, aldosterone attenuated insulin-induced Akt phosphorylation in 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes in a dose-dependent manner (P < 0.01). These effects were ameliorated by pretreatment with esaxerenone. Conclusion: Esaxerenone ameliorated insulin resistance in HFD-fed mice. Reduction of inflammation and improvement in insulin signaling may underlie the beneficial effects of esaxerenone.
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1016/j.ejphar.2022.175190
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/117375/20231024134330832651/k3756_abstract.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/117375/2023102413433112823/k3756_review.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/117375/20231024134331306551/k3756_fulltext.pdf fulltext